Connection

Angelo Avogaro to Hypoglycemic Agents

Back to Details
This is a "connection" page, showing publications Angelo Avogaro has written about Hypoglycemic Agents.
Angelo Avogaro
Connection Strength
3.674
Hypoglycemic Agents
  1. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. J Am Heart Assoc. 2019 07 16; 8(14):e012244.
    View in: PubMed
    Score: 0.312
  2. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. Diabetes Obes Metab. 2018 Jun; 20(6):1367-1368.
    View in: PubMed
    Score: 0.284
  3. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. Diabetes Metab Res Rev. 2018 05; 34(4):e2981.
    View in: PubMed
    Score: 0.284
  4. Keeping the right track in the treatment of patients with type 2 diabetes. Eur J Heart Fail. 2018 01; 20(1):52-54.
    View in: PubMed
    Score: 0.281
  5. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017 09; 5(9):680-681.
    View in: PubMed
    Score: 0.273
  6. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017 08; 60(8):1385-1389.
    View in: PubMed
    Score: 0.269
  7. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol. 2017 Jul; 10(7):763-772.
    View in: PubMed
    Score: 0.269
  8. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opin Pharmacother. 2017 Apr; 18(5):517-527.
    View in: PubMed
    Score: 0.266
  9. Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes. J Clin Endocrinol Metab. 2016 Feb; 101(2):748-56.
    View in: PubMed
    Score: 0.244
  10. Managing diabetes in diabetic patients with COVID: where do we start from? Acta Diabetol. 2021 Nov; 58(11):1441-1450.
    View in: PubMed
    Score: 0.090
  11. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. Diabetes Obes Metab. 2019 11; 21(11):2542-2552.
    View in: PubMed
    Score: 0.079
  12. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol. 2019 Jun; 56(6):605-617.
    View in: PubMed
    Score: 0.075
  13. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes Obes Metab. 2019 02; 21(2):252-260.
    View in: PubMed
    Score: 0.074
  14. Exposure to insulin degludec during pregnancy: report of a small series and review of the literature. J Endocrinol Invest. 2019 Mar; 42(3):345-349.
    View in: PubMed
    Score: 0.073
  15. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes Obes Metab. 2018 07; 20(7):1781-1786.
    View in: PubMed
    Score: 0.072
  16. The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetol. 2018 Jun; 55(6):593-601.
    View in: PubMed
    Score: 0.071
  17. Insulin treatment in patients with diabetes and heart failure: defendant on the stand. Eur J Heart Fail. 2018 05; 20(5):896-897.
    View in: PubMed
    Score: 0.071
  18. Effects of Hypoglycemia on Circulating Stem and Progenitor Cells in Diabetic Patients. J Clin Endocrinol Metab. 2018 03 01; 103(3):1048-1055.
    View in: PubMed
    Score: 0.071
  19. Head-to-head comparison of the accuracy of Abbott FreeStyle Libre and Dexcom G5 mobile. Nutr Metab Cardiovasc Dis. 2018 04; 28(4):425-427.
    View in: PubMed
    Score: 0.071
  20. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2018 03; 20(3):740-744.
    View in: PubMed
    Score: 0.070
  21. Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes. J Clin Endocrinol Metab. 2017 10 01; 102(10):3674-3682.
    View in: PubMed
    Score: 0.069
  22. Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis. 2017 Dec; 27(12):1089-1097.
    View in: PubMed
    Score: 0.068
  23. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes Metab. 2018 01; 20(1):25-33.
    View in: PubMed
    Score: 0.068
  24. Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017 Aug 15; 241:450-456.
    View in: PubMed
    Score: 0.067
  25. [Cardiovascular disease in diabetic patients: risk factors, clinical history and prevention]. G Ital Cardiol (Rome). 2016 Dec; 17(12 Suppl 2):3S-12.
    View in: PubMed
    Score: 0.065
  26. Efficacy of telemedicine for persons with type 1 diabetes during Covid19 lockdown. Nutr Diabetes. 2021 01 05; 11(1):1.
    View in: PubMed
    Score: 0.022
  27. FreeStyle Libre and Dexcom G4 Platinum sensors: Accuracy comparisons during two weeks of home use and use during experimentally induced glucose excursions. Nutr Metab Cardiovasc Dis. 2018 02; 28(2):180-186.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.